Quest sued by Myriad in flap over BRCA test patents

Myriad Genetics ($MYGN) is suing Quest Diagnostics ($DGX) for alleged patent violations involving its BRCA-related cancer diagnostic test. Quest was ready for the legal action, having preemptively filed a complaint a few weeks ago seeking to determine that its new test didn't violate any Myriad patents. Myriad is currently suing three other companies in related cases, including Bioreference Laboratories, Gene By Gene and Ambry Genetics. All four of the defendants launched BRCA-related tests in the wake of a U.S. Supreme Court decision earlier this year that invalidated some Myriad patents in the space but upheld others. Myriad alleges that Quest's testing process infringes on patents held by it and its partners involving the screening of BRCA1 and BRCA2 genes. Quest pledged to fight Myriad's lawsuit. Story

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.